Table 3.
The Percent of People with Three Chronic Illnesses Using Prescription Medications, by Managed Care and Indemnity Health Insurance and by Age, 1997
| Younger Than Age 65 | Aged 65 and Older | |||
|---|---|---|---|---|
| Managed Care | Indemnity | Managed Care | Indemnity | |
| Diabetes Mellitus | ||||
| (Number of members) | (11,015) | (3,249) | (4,989) | (7,191) |
| Sulfonylureas 1st† | 0.9 | 0.6 | 2.4 | 2.0 |
| Sulfonylureas 2d† | 41.4 | 31.1*** | 42.7 | 39.6*** |
| Metformin | 29.1 | 18.8*** | 19.8 | 17.6** |
| Troglitizone | 9.7 | 7.0*** | 6.9 | 6.2 |
| Insulin | 25.3 | 21.1*** | 16.5 | 21.2*** |
| Any DM medication | 74.6 | 58.1*** | 66.8 | 66.3 |
| Congestive Heart Failure | ||||
| (Number of members) | (1,041) | (455) | (1,834) | (4,648) |
| Loop diuretics | 42.8 | 31.2*** | 46.2 | 41.9** |
| ACE inhibitors | 52.6 | 37.8*** | 42.3 | 37.5*** |
| ARBs | 6.1 | 3.3* | 3.1 | 3.2 |
| Beta-blockers§ | 25.5 | 16.7*** | 21.8 | 15.5*** |
| Carvedilol | 3.9 | 1.5* | 1.2 | 1.1 |
| Digoxin | 31.1 | 24.8* | 33.1 | 32.9 |
| Any CHF medication | 72.0 | 52.1*** | 63.1 | 56.4*** |
| Asthma | ||||
| (Number of members) | (7,401) | (1,344) | (468) | (637) |
| Inhaled corticosteroids | 34.4 | 29.0*** | 35.3 | 31.6 |
| Systemic corticosteroids | 17.8 | 14.9** | 20.5 | 17.1 |
| Short-acting beta-agonists | 42.6 | 33.9*** | 34.0 | 31.1 |
| Long-acting beta-agonists | 10.0 | 7.9* | 10.3 | 10.4 |
| Leukotriene modifiers | 5.5 | 3.9* | 4.5 | 4.6 |
| Cromolyn | 5.0 | 4.8 | 2.8 | 4.1 |
| Methylxanthines | 9.0 | 8.0 | 12.4 | 11.5 |
| Any asthma medication | 56.9 | 45.5*** | 53.9 | 48.2 |
*
Statistically significant between managed care and indemnity at p< 0.05.
**
Statistically significant between managed care and indemnity at p< 0.01.
***
Statistically significant between managed care and indemnity at p< 0.001.
†
Sulfonylureas 1st refers to first-generation medications in this class, while Sulfonylureas 2d refers to second-generation medications in this class.
§
Excluding carvedilol.